Sparks commentary - Cantargia

Healthcare

Sparks - Cantargia

More on this equity
Cantargia (OMX: CANTA) breast cancer study fully recruited
Published by Arron Aatkar, PhD

Cantargia has announced that it has completed recruiting patients (n=102) for the randomised Phase II TRIFOUR trial, which is evaluating nadunolimab in combination with platinum-based chemotherapy, compared to chemotherapy alone, in triple negative breast cancer. The initial efficacy results are anticipated from mid-2025, potentially representing a near-term catalyst for the company.

The prior interim update from the Phase Ib dose-finding portion of the programme (n=15) were encouraging, showing an overall response rate of 60%, median progression-free survival of 6.6 months and overall survival of 12.8 months.

Latest

Healthcare | Comment

Cantargia (OMX: CANTA) enrols first patient in leukaemia study

Industrials | Comment

NWF (LON: NWF) acquires Northern Energy Oil

Healthcare | Comment

Cantargia (OMX: CANTA) reports positive CAN10 update

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free